,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['breast', 'enhertu']
enhertu already delivered several outstanding results in her2-positive breast cancer and now shown an impressive survival benefit over chemotherapy in patients considered her2-negative, with the data holding up even in those with the very lowest expression 